Related Experiment Video
Updated: Aug 7, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Selective inhibitors of hepatitis C virus replication
1Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. johan.neyts@rega.kuleuven.be
Abstract:
Worldwide over 170 million people are chronically infected with the hepatitis C virus and hence at high risk to develop fatal liver disease. There is no vaccine available and the standard therapy [(pegylated) interferon alfa plus ribavirin] is only effective in 50-60% of patients and is associated with important side-effects. The discovery of novel antiviral strategies to selectively inhibit HCV replication has long been hindered by the lack of convenient cell culture models for the propagation of HCV. This hurdle has been overcome first with the establishment of the HCV replicon system in 1999 and, in 2005, with the development of robust HCV cell culture models. In recent years also mouse models have been elaborated that will be instrumental in assessing the in vivo efficacy of novel drugs. The viral serine protease and the viral RNA dependent RNA polymerase have shown to be excellent targets for selective anti-HCV therapy. Clinical studies with a limited number of HCV protease and polymerase inhibitors resulted in encouraging results. However, and not unexpected, preclinical evidence suggest that the virus may become rapidly resistant to such inhibitors. Combination therapy of drugs with different mode of action and resistance profiles may thus be required. Alternative strategies, such as the use of non-immunosuppressive cyclosporin A analogues with potent anti-HCV activity, may prove important, in particular since such compounds may have a resistance profile that is very different from that of protease or polymerase inhibitors.
Insights
Hepatitis C virus (HCV) infection affects millions globally. New therapies targeting viral protease and polymerase show promise, but drug resistance necessitates combination treatments or alternative strategies like cyclosporin A analogues.
Area of Science:
- Hepatology
- Virology
- Drug Discovery
Background:
- Hepatitis C virus (HCV) chronically infects over 170 million people worldwide, posing a significant risk for fatal liver disease.
- Current standard therapy (pegylated interferon alfa plus ribavirin) exhibits limited efficacy (50-60%) and notable side effects.
- Development of effective antiviral strategies was historically impeded by a lack of suitable cell culture models for HCV propagation.
Purpose of the Study:
- To review advancements in HCV research, focusing on novel antiviral strategies and therapeutic targets.
- To discuss the development and importance of HCV cell culture and mouse models in drug efficacy assessment.
- To explore potential therapeutic approaches, including combination therapies and alternative agents like cyclosporin A analogues.
Main Methods:
- Establishment of the HCV replicon system (1999) and robust HCV cell culture models (2005) facilitated research.
- Development of mouse models for in vivo efficacy assessment of novel antiviral drugs.
- Investigation of viral serine protease and RNA-dependent RNA polymerase as key therapeutic targets.
Main Results:
- HCV protease and polymerase inhibitors have demonstrated encouraging results in early clinical studies.
- Preclinical data indicate a high potential for rapid development of viral resistance to these inhibitors.
- Alternative strategies, such as non-immunosuppressive cyclosporin A analogues, show potent anti-HCV activity and distinct resistance profiles.
Conclusions:
- Combination therapy with drugs having different mechanisms of action and resistance profiles is likely essential for effective HCV treatment.
- Alternative antiviral strategies, exemplified by cyclosporin A analogues, offer a promising avenue, particularly due to their potentially different resistance patterns compared to protease or polymerase inhibitors.
- Continued research into novel therapeutic targets and combination strategies is crucial for overcoming HCV and managing drug resistance.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:22Antiviral Nucleoside Inhibitors
01:25Hepatitis
01:25Inhibitors Of Virion Release
01:19Inhibitors of Virion Maturation and Assembly
01:28Inhibitors of Bacterial DNA Synthesis